US FDA's proposed rule on post-market safety reporting for combination products appears to finally be making its way to the top of the queue, with the agency acknowledging that it is among the next steps in modernizing the combination products review program.
The rule – which was first proposed in 2009 – aims to clarify post-marketing safety reporting requirements for such products by spelling out the types of alerts that should be reported to FDA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?